AKT/PKB Signaling: Navigating the Network

Cell

Volumn 169, Issue 3, 2017, Pages 381-405

  Manning, Brendan D ^a   Toker, Alex ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR FOXO; TUBERIN; ISOENZYME;

ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SUBSTRATE; FEEDBACK SYSTEM; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG THERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION;

ANIMALS; DRUG THERAPY; HUMANS; ISOENZYMES; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 85018509261     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.04.001     Document Type: Review

References (291)

1. Abdallah, C.G., Sanacora, G., Duman, R.S., Krystal, J.H., Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 66 (2015), 509–523.
2. Ackah, E., Yu, J., Zoellner, S., Iwakiri, Y., Skurk, C., Shibata, R., Ouchi, N., Easton, R.M., Galasso, G., Birnbaum, M.J., et al. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 115 (2005), 2119–2127.
3. Alessi, D.R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., Hemmings, B.A., Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15 (1996), 6541–6551.
4. Alessi, D.R., Caudwell, F.B., Andjelkovic, M., Hemmings, B.A., Cohen, P., Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett. 399 (1996), 333–338.
5. Alessi, D.R., James, S.R., Downes, C.P., Holmes, A.B., Gaffney, P.R., Reese, C.B., Cohen, P., Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7 (1997), 261–269.
6. Altomare, D.A., Testa, J.R., Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 (2005), 7455–7464.
7. Amin, R.H., Schlissel, M.S., Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat. Immunol. 9 (2008), 613–622.
8. An, W.L., Cowburn, R.F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.G., Winblad, B., Pei, J.J., Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 163 (2003), 591–607.
9. Andjelković, M., Jakubowicz, T., Cron, P., Ming, X.F., Han, J.W., Hemmings, B.A., Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc. Natl. Acad. Sci. USA 93 (1996), 5699–5704.
10. Arranz, A., Doxaki, C., Vergadi, E., Martinez de la Torre, Y., Vaporidi, K., Lagoudaki, E.D., Ieronymaki, E., Androulidaki, A., Venihaki, M., Margioris, A.N., et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc. Natl. Acad. Sci. USA 109 (2012), 9517–9522.
11. Auger, K.R., Serunian, L.A., Soltoff, S.P., Libby, P., Cantley, L.C., PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57 (1989), 167–175.
12. Babaev, V.R., Hebron, K.E., Wiese, C.B., Toth, C.L., Ding, L., Zhang, Y., May, J.M., Fazio, S., Vickers, K.C., Linton, M.F., Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. J. Lipid Res. 55 (2014), 2296–2308.
13. Bago, R., Sommer, E., Castel, P., Crafter, C., Bailey, F.P., Shpiro, N., Baselga, J., Cross, D., Eyers, P.A., Alessi, D.R., The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. EMBO J., 35, 2016, 2263.
14. Barnett, S.F., Defeo-Jones, D., Fu, S., Hancock, P.J., Haskell, K.M., Jones, R.E., Kahana, J.A., Kral, A.M., Leander, K., Lee, L.L., et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385 (2005), 399–408.
15. Bellacosa, A., Testa, J.R., Staal, S.P., Tsichlis, P.N., A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254 (1991), 274–277.
16. Bentzinger, C.F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J.B., Oliveri, F., Xia, J., Casanova, E., Costa, C.F., Brink, M., et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 8 (2008), 411–424.
17. Berwick, D.C., Hers, I., Heesom, K.J., Moule, S.K., Tavare, J.M., The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J. Biol. Chem. 277 (2002), 33895–33900.
18. Blouet, C., Ono, H., Schwartz, G.J., Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. Cell Metab. 8 (2008), 459–467.
19. Borlado, L.R., Redondo, C., Alvarez, B., Jimenez, C., Criado, L.M., Flores, J., Marcos, M.A., Martinez-A, C., Balomenos, D., Carrera, A.C., Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14 (2000), 895–903.
20. Bozulic, L., Surucu, B., Hynx, D., Hemmings, B.A., PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol. Cell 30 (2008), 203–213.
21. Braccini, L., Ciraolo, E., Campa, C.C., Perino, A., Longo, D.L., Tibolla, G., Pregnolato, M., Cao, Y., Tassone, B., Damilano, F., et al. PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat. Commun., 6, 2015, 7400.
22. Brognard, J., Sierecki, E., Gao, T., Newton, A.C., PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 25 (2007), 917–931.
23. Brunet, A., Bonni, A., Zigmond, M.J., Lin, M.Z., Juo, P., Hu, L.S., Anderson, M.J., Arden, K.C., Blenis, J., Greenberg, M.E., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999), 857–868.
24. Brunet, A., Park, J., Tran, H., Hu, L.S., Hemmings, B.A., Greenberg, M.E., Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol. Cell. Biol. 21 (2001), 952–965.
25. Brunn, G.J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J.C. Jr., Abraham, R.T., Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15 (1996), 5256–5267.
26. Burgering, B.M., Coffer, P.J., Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376 (1995), 599–602.
27. Buzzi, F., Xu, L., Zuellig, R.A., Boller, S.B., Spinas, G.A., Hynx, D., Chang, Z., Yang, Z., Hemmings, B.A., Tschopp, O., Niessen, M., Differential effects of protein kinase B/Akt isoforms on glucose homeostasis and islet mass. Mol. Cell. Biol. 30 (2010), 601–612.
28. Byles, V., Covarrubias, A.J., Ben-Sahra, I., Lamming, D.W., Sabatini, D.M., Manning, B.D., Horng, T., The TSC-mTOR pathway regulates macrophage polarization. Nat. Commun., 4, 2013, 2834.
29. Calamito, M., Juntilla, M.M., Thomas, M., Northrup, D.L., Rathmell, J., Birnbaum, M.J., Koretzky, G., Allman, D., Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood 115 (2010), 4043–4050.
30. Calera, M.R., Martinez, C., Liu, H., Jack, A.K., Birnbaum, M.J., Pilch, P.F., Insulin increases the association of Akt-2 with Glut4-containing vesicles. J. Biol. Chem. 273 (1998), 7201–7204.
31. Calleja, V., Alcor, D., Laguerre, M., Park, J., Vojnovic, B., Hemmings, B.A., Downward, J., Parker, P.J., Larijani, B., Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol., 5, 2007, e95.
32. Calleja, V., Laguerre, M., Parker, P.J., Larijani, B., Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol., 7, 2009, e17.
33. Cantley, L.C., The role of phosphoinositide 3-kinase in human disease. Harvey Lect. 100 (2004–2005), 103–122.
34. Carpten, J.D., Faber, A.L., Horn, C., Donoho, G.P., Briggs, S.L., Robbins, C.M., Hostetter, G., Boguslawski, S., Moses, T.Y., Savage, S., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007), 439–444.
35. Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F.J., Kannan, S., Verma, C.S., Dickler, M., Chandarlapaty, S., et al. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell 30 (2016), 229–242.
36. Castets, P., Lin, S., Rion, N., Di Fulvio, S., Romanino, K., Guridi, M., Frank, S., Tintignac, L.A., Sinnreich, M., Rüegg, M.A., Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab. 17 (2013), 731–744.
37. Chakrabarti, P., English, T., Shi, J., Smas, C.M., Kandror, K.V., Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes 59 (2010), 775–781.
38. Chan, C.H., Li, C.F., Yang, W.L., Gao, Y., Lee, S.W., Feng, Z., Huang, H.Y., Tsai, K.K., Flores, L.G., Shao, Y., et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149 (2012), 1098–1111.
39. Chan, C.H., Jo, U., Kohrman, A., Rezaeian, A.H., Chou, P.C., Logothetis, C., Lin, H.K., Posttranslational regulation of Akt in human cancer. Cell Biosci., 4, 2014, 59.
40. Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P.K., Baselga, J., Rosen, N., AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19 (2011), 58–71.
41. Chavez, J.A., Roach, W.G., Keller, S.R., Lane, W.S., Lienhard, G.E., Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation. J. Biol. Chem. 283 (2008), 9187–9195.
42. Chen, W.S., Xu, P.Z., Gottlob, K., Chen, M.L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15 (2001), 2203–2208.
43. Chen, J., Somanath, P.R., Razorenova, O., Chen, W.S., Hay, N., Bornstein, P., Byzova, T.V., Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat. Med. 11 (2005), 1188–1196.
44. Chen, M.L., Xu, P.Z., Peng, X.D., Chen, W.S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P.P., Hay, N., The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20 (2006), 1569–1574.
45. Chen, J., Limon, J.J., Blanc, C., Peng, S.L., Fruman, D.A., Foxo1 regulates marginal zone B-cell development. Eur. J. Immunol. 40 (2010), 1890–1896.
46. Chen, J., Tang, H., Hay, N., Xu, J., Ye, R.D., Akt isoforms differentially regulate neutrophil functions. Blood 115 (2010), 4237–4246.
47. Chen, M., Pratt, C.P., Zeeman, M.E., Schultz, N., Taylor, B.S., O'Neill, A., Castillo-Martin, M., Nowak, D.G., Naguib, A., Grace, D.M., et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 20 (2011), 173–186.
48. Chiang, G.G., Abraham, R.T., Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280 (2005), 25485–25490.
49. Chin, Y.R., Yuan, X., Balk, S.P., Toker, A., PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov. 4 (2014), 942–955.
50. Cho, H., Mu, J., Kim, J.K., Thorvaldsen, J.L., Chu, Q., Crenshaw, E.B. 3rd, Kaestner, K.H., Bartolomei, M.S., Shulman, G.I., Birnbaum, M.J., Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292 (2001), 1728–1731.
51. Cho, H., Thorvaldsen, J.L., Chu, Q., Feng, F., Birnbaum, M.J., Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276 (2001), 38349–38352.
52. Choi, Y.H., Park, S., Hockman, S., Zmuda-Trzebiatowska, E., Svennelid, F., Haluzik, M., Gavrilova, O., Ahmad, F., Pepin, L., Napolitano, M., et al. Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J. Clin. Invest. 116 (2006), 3240–3251.
53. Cingolani, F., Czaja, M.J., Regulation and Functions of Autophagic Lipolysis. Trends Endocrinol. Metab. 27 (2016), 696–705.
54. Coffer, P.J., Woodgett, J.R., Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. J. Biochem. 201 (1991), 475–481.
55. Collins, B.J., Deak, M., Arthur, J.S., Armit, L.J., Alessi, D.R., In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 22 (2003), 4202–4211.
56. Cota, D., Proulx, K., Smith, K.A., Kozma, S.C., Thomas, G., Woods, S.C., Seeley, R.J., Hypothalamic mTOR signaling regulates food intake. Science 312 (2006), 927–930.
57. Covarrubias, A.J., Aksoylar, H.I., Horng, T., Control of macrophage metabolism and activation by mTOR and Akt signaling. Semin. Immunol. 27 (2015), 286–296.
58. Covarrubias, A.J., Aksoylar, H.I., Yu, J., Snyder, N.W., Worth, A.J., Iyer, S.S., Wang, J., Ben-Sahra, I., Byles, V., Polynne-Stapornkul, T., et al. Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. eLife, 5, 2016, e11612.
59. Crabb, S.J., Birtle, A.J., Martin, K., Downs, N., Ratcliffe, I., Maishman, T., Ellis, M., Griffiths, G., Thompson, S., Ksiazek, L., et al. ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. Invest. New Drugs, 2017, 10.1007/s10637-017-0433-4 Published online February 1, 2017.
60. Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., Hemmings, B.A., Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995), 785–789.
61. Crouthamel, M.C., Kahana, J.A., Korenchuk, S., Zhang, S.Y., Sundaresan, G., Eberwein, D.J., Brown, K.K., Kumar, R., Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin. Cancer Res. 15 (2009), 217–225.
62. Czech, M.P., Tencerova, M., Pedersen, D.J., Aouadi, M., Insulin signalling mechanisms for triacylglycerol storage. Diabetologia 56 (2013), 949–964.
63. Dajani, R., Fraser, E., Roe, S.M., Young, N., Good, V., Dale, T.C., Pearl, L.H., Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105 (2001), 721–732.
64. Datta, S.R., Katsov, A., Hu, L., Petros, A., Fesik, S.W., Yaffe, M.B., Greenberg, M.E., 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol. Cell 6 (2000), 41–51.
65. Davies, M.A., Stemke-Hale, K., Tellez, C., Calderone, T.L., Deng, W., Prieto, V.G., Lazar, A.J., Gershenwald, J.E., Mills, G.B., A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 99 (2008), 1265–1268.
66. Davies, B.R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 11 (2012), 873–887.
67. Delgoffe, G.M., Kole, T.P., Zheng, Y., Zarek, P.E., Matthews, K.L., Xiao, B., Worley, P.F., Kozma, S.C., Powell, J.D., The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30 (2009), 832–844.
68. Delgoffe, G.M., Pollizzi, K.N., Waickman, A.T., Heikamp, E., Meyers, D.J., Horton, M.R., Xiao, B., Worley, P.F., Powell, J.D., The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12 (2011), 295–303.
69. Di Maira, G., Salvi, M., Arrigoni, G., Marin, O., Sarno, S., Brustolon, F., Pinna, L.A., Ruzzene, M., Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 12 (2005), 668–677.
70. Dibble, C.C., Manning, B.D., Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol. 15 (2013), 555–564.
71. Dibble, C.C., Asara, J.M., Manning, B.D., Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol. Cell. Biol. 29 (2009), 5657–5670.
72. Dillon, R.L., Marcotte, R., Hennessy, B.T., Woodgett, J.R., Mills, G.B., Muller, W.J., Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 69 (2009), 5057–5064.
73. Ding, Q., He, X., Hsu, J.M., Xia, W., Chen, C.T., Li, L.Y., Lee, D.F., Liu, J.C., Zhong, Q., Wang, X., Hung, M.C., Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 27 (2007), 4006–4017.
74. Ding, L., Biswas, S., Morton, R.E., Smith, J.D., Hay, N., Byzova, T.V., Febbraio, M., Podrez, E.A., Akt3 deficiency in macrophages promotes foam cell formation and atherosclerosis in mice. Cell Metab. 15 (2012), 861–872.
75. DiPilato, L.M., Ahmad, F., Harms, M., Seale, P., Manganiello, V., Birnbaum, M.J., The Role of PDE3B Phosphorylation in the Inhibition of Lipolysis by Insulin. Mol. Cell. Biol. 35 (2015), 2752–2760.
76. Dumaz, N., Marais, R., Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 278 (2003), 29819–29823.
77. Dumble, M., Crouthamel, M.C., Zhang, S.Y., Schaber, M., Levy, D., Robell, K., Liu, Q., Figueroa, D.J., Minthorn, E.A., Seefeld, M.A., et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS ONE, 9, 2014, e100880.
78. Dummler, B., Hemmings, B.A., Physiological roles of PKB/Akt isoforms in development and disease. Biochem. Soc. Trans. 35 (2007), 231–235.
79. Dummler, B., Tschopp, O., Hynx, D., Yang, Z.Z., Dirnhofer, S., Hemmings, B.A., Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell. Biol. 26 (2006), 8042–8051.
80. Düvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39 (2010), 171–183.
81. Easton, R.M., Cho, H., Roovers, K., Shineman, D.W., Mizrahi, M., Forman, M.S., Lee, V.M., Szabolcs, M., de Jong, R., Oltersdorf, T., et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol. Cell. Biol. 25 (2005), 1869–1878.
82. Ebner, M., Lučić, I., Leonard, T.A., Yudushkin, I., PI(3,4,5)P3 Engagement Restricts Akt Activity to Cellular Membranes. Mol. Cell 65 (2017), 416–431.
83. Ebner, M., Sinkovics, B., Szczygieł, M., Ribeiro, D.W., Yudushkin, I., Localization of mTORC2 activity inside cells. J. Cell Biol. 216 (2017), 343–353.
84. Egerman, M.A., Glass, D.J., Signaling pathways controlling skeletal muscle mass. Crit. Rev. Biochem. Mol. Biol. 49 (2014), 59–68.
85. Eguez, L., Lee, A., Chavez, J.A., Miinea, C.P., Kane, S., Lienhard, G.E., McGraw, T.E., Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. Cell Metab. 2 (2005), 263–272.
86. Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M., Gogos, J.A., Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 36 (2004), 131–137.
87. Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A.C., Mao, Y., Miao, R.Q., et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27 (2008), 1932–1943.
88. Fan, W., Morinaga, H., Kim, J.J., Bae, E., Spann, N.J., Heinz, S., Glass, C.K., Olefsky, J.M., FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J. 29 (2010), 4223–4236.
89. Fan, C.D., Lum, M.A., Xu, C., Black, J.D., Wang, X., Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. J. Biol. Chem. 288 (2013), 1674–1684.
90. Fedele, C.G., Ooms, L.M., Ho, M., Vieusseux, J., O'Toole, S.A., Millar, E.K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Natl. Acad. Sci. USA 107 (2010), 22231–22236.
91. Fernández-Hernando, C., Ackah, E., Yu, J., Suárez, Y., Murata, T., Iwakiri, Y., Prendergast, J., Miao, R.Q., Birnbaum, M.J., Sessa, W.C., Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab. 6 (2007), 446–457.
92. Fernández-Hernando, C., József, L., Jenkins, D., Di Lorenzo, A., Sessa, W.C., Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 2033–2040.
93. Fonseca, B.D., Smith, E.M., Lee, V.H., MacKintosh, C., Proud, C.G., PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J. Biol. Chem. 282 (2007), 24514–24524.
94. Frame, S., Cohen, P., Biondi, R.M., A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7 (2001), 1321–1327.
95. Franke, T.F., Yang, S.I., Chan, T.O., Datta, K., Kazlauskas, A., Morrison, D.K., Kaplan, D.R., Tsichlis, P.N., The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81 (1995), 727–736.
96. Franke, T.F., Kaplan, D.R., Cantley, L.C., Toker, A., Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275 (1997), 665–668.
97. Frech, M., Andjelkovic, M., Ingley, E., Reddy, K.K., Falck, J.R., Hemmings, B.A., High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J. Biol. Chem. 272 (1997), 8474–8481.
98. Gao, T., Furnari, F., Newton, A.C., PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 18 (2005), 13–24.
99. Garofalo, R.S., Orena, S.J., Rafidi, K., Torchia, A.J., Stock, J.L., Hildebrandt, A.L., Coskran, T., Black, S.C., Brees, D.J., Wicks, J.R., et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J. Clin. Invest. 112 (2003), 197–208.
100. George, S., Rochford, J.J., Wolfrum, C., Gray, S.L., Schinner, S., Wilson, J.C., Soos, M.A., Murgatroyd, P.R., Williams, R.M., Acerini, C.L., et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304 (2004), 1325–1328.
101. Gerriets, V.A., Kishton, R.J., Johnson, M.O., Cohen, S., Siska, P.J., Nichols, A.G., Warmoes, M.O., de Cubas, A.A., MacIver, N.J., Locasale, J.W., et al. Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat. Immunol. 17 (2016), 1459–1466.
102. Gewinner, C., Wang, Z.C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W.M., Rameh, L., Salmena, L., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16 (2009), 115–125.
103. Griffin, R.J., Moloney, A., Kelliher, M., Johnston, J.A., Ravid, R., Dockery, P., O'Connor, R., O'Neill, C., Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93 (2005), 105–117.
104. Guan, K.L., Figueroa, C., Brtva, T.R., Zhu, T., Taylor, J., Barber, T.D., Vojtek, A.B., Negative regulation of the serine/threonine kinase B-Raf by Akt. J. Biol. Chem. 275 (2000), 27354–27359.
105. Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Fitzgerald, K.J., Sabatini, D.M., Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 11 (2006), 859–871.
106. Guilherme, A., Klarlund, J.K., Krystal, G., Czech, M.P., Regulation of phosphatidylinositol 3,4,5-trisphosphate 5’-phosphatase activity by insulin. J. Biol. Chem. 271 (1996), 29533–29536.
107. Gulen, M.F., Bulek, K., Xiao, H., Yu, M., Gao, J., Sun, L., Beurel, E., Kaidanovich-Beilin, O., Fox, P.L., DiCorleto, P.E., et al. Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 37 (2012), 800–812.
108. Guo, H., Gao, M., Lu, Y., Liang, J., Lorenzi, P.L., Bai, S., Hawke, D.H., Li, J., Dogruluk, T., Scott, K.L., et al. Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene 33 (2014), 3463–3472.
109. Guo, J., Chakraborty, A.A., Liu, P., Gan, W., Zheng, X., Inuzuka, H., Wang, B., Zhang, J., Zhang, L., Yuan, M., et al. pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. Science 353 (2016), 929–932.
110. Harrington, L.S., Findlay, G.M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N.R., Cheng, S., Shepherd, P.R., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2004), 213–223.
111. Hawkins, P.T., Stephens, L.R., Emerging evidence of signalling roles for PI(3,4)P2 in Class I and II PI3K-regulated pathways. Biochem. Soc. Trans. 44 (2016), 307–314.
112. Hawley, S.A., Ross, F.A., Gowans, G.J., Tibarewal, P., Leslie, N.R., Hardie, D.G., Phosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells. Biochem. J. 459 (2014), 275–287.
113. Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P.K., Pan, B.S., Kotani, H., MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9 (2010), 1956–1967.
114. Hirsch, E., Katanaev, V.L., Garlanda, C., Azzolino, O., Pirola, L., Silengo, L., Sozzani, S., Mantovani, A., Altruda, F., Wymann, M.P., Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287 (2000), 1049–1053.
115. Holz, M.K., Blenis, J., Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280 (2005), 26089–26093.
116. Horman, S., Vertommen, D., Heath, R., Neumann, D., Mouton, V., Woods, A., Schlattner, U., Wallimann, T., Carling, D., Hue, L., Rider, M.H., Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J. Biol. Chem. 281 (2006), 5335–5340.
117. Hou, L., Klann, E., Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 24 (2004), 6352–6361.
118. Howell, J.J., Manning, B.D., mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol. Metab. 22 (2011), 94–102.
119. Hsu, P.P., Kang, S.A., Rameseder, J., Zhang, Y., Ottina, K.A., Lim, D., Peterson, T.R., Choi, Y., Gray, N.S., Yaffe, M.B., et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332 (2011), 1317–1322.
120. Huang, J., Dibble, C.C., Matsuzaki, M., Manning, B.D., The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 28 (2008), 4104–4115.
121. Hussain, K., Challis, B., Rocha, N., Payne, F., Minic, M., Thompson, A., Daly, A., Scott, C., Harris, J., Smillie, B.J., et al. An activating mutation of AKT2 and human hypoglycemia. Science, 334, 2011, 474.
122. Hutchinson, J.N., Jin, J., Cardiff, R.D., Woodgett, J.R., Muller, W.J., Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 64 (2004), 3171–3178.
123. Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., Guan, K.L., Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27 (2008), 1919–1931.
124. Inoki, K., Li, Y., Zhu, T., Wu, J., Guan, K.L., TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4 (2002), 648–657.
125. Irie, H.Y., Pearline, R.V., Grueneberg, D., Hsia, M., Ravichandran, P., Kothari, N., Natesan, S., Brugge, J.S., Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 171 (2005), 1023–1034.
126. Izumiya, Y., Hopkins, T., Morris, C., Sato, K., Zeng, L., Viereck, J., Hamilton, J.A., Ouchi, N., LeBrasseur, N.K., Walsh, K., Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab. 7 (2008), 159–172.
127. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J., Su, B., SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006), 125–137.
128. Jagannath, C., Lindsey, D.R., Dhandayuthapani, S., Xu, Y., Hunter, R.L. Jr., Eissa, N.T., Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat. Med. 15 (2009), 267–276.
129. James, S.R., Downes, C.P., Gigg, R., Grove, S.J.A., Holmes, A.B., Alessi, D.R., Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem. J. 315 (1996), 709–713.
130. Jethwa, N., Chung, G.H., Lete, M.G., Alonso, A., Byrne, R.D., Calleja, V., Larijani, B., Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway. J. Cell Sci. 128 (2015), 3456–3465.
131. Jiang, H., Guo, W., Liang, X., Rao, Y., Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell 120 (2005), 123–135.
132. Jiang, H., Westerterp, M., Wang, C., Zhu, Y., Ai, D., Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. Diabetologia 57 (2014), 2393–2404.
133. Jones, P.F., Jakubowicz, T., Pitossi, F.J., Maurer, F., Hemmings, B.A., Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc. Natl. Acad. Sci. USA 88 (1991), 4171–4175.
134. Julien, L.A., Carriere, A., Moreau, J., Roux, P.P., mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 30 (2010), 908–921.
135. Juntilla, M.M., Wofford, J.A., Birnbaum, M.J., Rathmell, J.C., Koretzky, G.A., Akt1 and Akt2 are required for alphabeta thymocyte survival and differentiation. Proc. Natl. Acad. Sci. USA 104 (2007), 12105–12110.
136. Kaidanovich-Beilin, O., Woodgett, J.R., GSK-3: Functional Insights from Cell Biology and Animal Models. Front. Mol. Neurosci., 4, 2011, 40.
137. Keppler-Noreuil, K.M., Sapp, J.C., Lindhurst, M.J., Parker, V.E., Blumhorst, C., Darling, T., Tosi, L.L., Huson, S.M., Whitehouse, R.W., Jakkula, E., et al. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am. J. Med. Genet. A. 164A (2014), 1713–1733.
138. Kerdiles, Y.M., Stone, E.L., Beisner, D.R., McGargill, M.A., Ch'en, I.L., Stockmann, C., Katayama, C.D., Hedrick, S.M., Foxo transcription factors control regulatory T cell development and function. Immunity 33 (2010), 890–904.
139. Kidani, Y., Elsaesser, H., Hock, M.B., Vergnes, L., Williams, K.J., Argus, J.P., Marbois, B.N., Komisopoulou, E., Wilson, E.B., Osborne, T.F., et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat. Immunol. 14 (2013), 489–499.
140. Kim, M.S., Pak, Y.K., Jang, P.G., Namkoong, C., Choi, Y.S., Won, J.C., Kim, K.S., Kim, S.W., Kim, H.S., Park, J.Y., et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat. Neurosci. 9 (2006), 901–906.
141. Kim, E.K., Yun, S.J., Ha, J.M., Kim, Y.W., Jin, I.H., Yun, J., Shin, H.K., Song, S.H., Kim, J.H., Lee, J.S., et al. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis. Oncogene 30 (2011), 2954–2963.
142. Kitamura, T., Kitamura, Y., Kuroda, S., Hino, Y., Ando, M., Kotani, K., Konishi, H., Matsuzaki, H., Kikkawa, U., Ogawa, W., Kasuga, M., Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol. Cell. Biol. 19 (1999), 6286–6296.
143. Klippel, A., Kavanaugh, W.M., Pot, D., Williams, L.T., A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol. Cell. Biol. 17 (1997), 338–344.
144. Kohn, A.D., Kovacina, K.S., Roth, R.A., Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing ser/thr kinase. EMBO J. 14 (1995), 4288–4295.
145. Kops, G.J., de Ruiter, N.D., De Vries-Smits, A.M., Powell, D.R., Bos, J.L., Burgering, B.M., Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398 (1999), 630–634.
146. Koren, S., DiPilato, L.M., Emmett, M.J., Shearin, A.L., Chu, Q., Monks, B., Birnbaum, M.J., The role of mouse Akt2 in insulin-dependent suppression of adipocyte lipolysis in vivo. Diabetologia 58 (2015), 1063–1070.
147. Kovacina, K.S., Park, G.Y., Bae, S.S., Guzzetta, A.W., Schaefer, E., Birnbaum, M.J., Roth, R.A., Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278 (2003), 10189–10194.
148. Kumar, A., Lawrence, J.C. Jr., Jung, D.Y., Ko, H.J., Keller, S.R., Kim, J.K., Magnuson, M.A., Harris, T.E., Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 59 (2010), 1397–1406.
149. Kunkel, M.T., Ni, Q., Tsien, R.Y., Zhang, J., Newton, A.C., Spatio-temporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter. J. Biol. Chem. 280 (2005), 5581–5587.
150. Kuo, Y.C., Huang, K.Y., Yang, C.H., Yang, Y.S., Lee, W.Y., Chiang, C.W., Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J. Biol. Chem. 283 (2008), 1882–1892.
151. Landgraf, K.E., Pilling, C., Falke, J.J., Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 47 (2008), 12260–12269.
152. Lapierre, J.M., Eathiraj, S., Vensel, D., Liu, Y., Bull, C.O., Cornell-Kennon, S., Iimura, S., Kelleher, E.W., Kizer, D.E., Koerner, S., et al. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J. Med. Chem. 59 (2016), 6455–6469.
153. Lauring, J., Cosgrove, D.P., Fontana, S., Gustin, J.P., Konishi, H., Abukhdeir, A.M., Garay, J.P., Mohseni, M., Wang, G.M., Higgins, M.J., et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 29 (2010), 2337–2345.
154. Leavens, K.F., Easton, R.M., Shulman, G.I., Previs, S.F., Birnbaum, M.J., Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 10 (2009), 405–418.
155. Lee, S.W., Dai, G., Hu, Z., Wang, X., Du, J., Mitch, W.E., Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J. Am. Soc. Nephrol. 15 (2004), 1537–1545.
156. Lee, M.Y., Luciano, A.K., Ackah, E., Rodriguez-Vita, J., Bancroft, T.A., Eichmann, A., Simons, M., Kyriakides, T.R., Morales-Ruiz, M., Sessa, W.C., Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates. Proc. Natl. Acad. Sci. USA 111 (2014), 12865–12870.
157. Leto, D., Saltiel, A.R., Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 13 (2012), 383–396.
158. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997), 1943–1947.
159. Li, Z., Jiang, H., Xie, W., Zhang, Z., Smrcka, A.V., Wu, D., Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287 (2000), 1046–1049.
160. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., Duman, R.S., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
161. Li, R., Wei, J., Jiang, C., Liu, D., Deng, L., Zhang, K., Wang, P., Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res. 73 (2013), 5742–5753.
162. Li Chew, C., Lunardi, A., Gulluni, F., Ruan, D.T., Chen, M., Salmena, L., Nishino, M., Papa, A., Ng, C., Fung, J., et al. In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. Cancer Discov. 5 (2015), 740–751.
163. Lien, E.C., Lyssiotis, C.A., Juvekar, A., Hu, H., Asara, J.M., Cantley, L.C., Toker, A., Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat. Cell Biol. 18 (2016), 572–578.
164. Lien, E.C., Dibble, C.C., Toker, A., PI3K signaling in cancer: beyond AKT. Curr. Opin. Cell Biol. 45 (2017), 62–71.
165. Lim, J.H., Jono, H., Komatsu, K., Woo, C.H., Lee, J., Miyata, M., Matsuno, T., Xu, X., Huang, Y., Zhang, W., et al. CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat. Commun., 3, 2012, 771.
166. Lin, K., Lin, J., Wu, W.I., Ballard, J., Lee, B.B., Gloor, S.L., Vigers, G.P., Morales, T.H., Friedman, L.S., Skelton, N., Brandhuber, B.J., An ATP-site on-off switch that restricts phosphatase accessibility of Akt. Sci. Signal., 5, 2012, ra37.
167. Lin, J., Sampath, D., Nannini, M.A., Lee, B.B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin. Cancer Res. 19 (2013), 1760–1772.
168. Lindhurst, M.J., Sapp, J.C., Teer, J.K., Johnston, J.J., Finn, E.M., Peters, K., Turner, J., Cannons, J.L., Bick, D., Blakemore, L., et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N. Engl. J. Med. 365 (2011), 611–619.
169. Lipton, J.O., Sahin, M., The neurology of mTOR. Neuron 84 (2014), 275–291.
170. Liu, L., Das, S., Losert, W., Parent, C.A., mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. Dev. Cell 19 (2010), 845–857.
171. Liu, G., Bi, Y., Wang, R., Shen, B., Zhang, Y., Yang, H., Wang, X., Liu, H., Lu, Y., Han, F., Kinase AKT1 negatively controls neutrophil recruitment and function in mice. J. Immunol. 191 (2013), 2680–2690.
172. Liu, P., Gan, W., Inuzuka, H., Lazorchak, A.S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat. Cell Biol. 15 (2013), 1340–1350.
173. Liu, P., Begley, M., Michowski, W., Inuzuka, H., Ginzberg, M., Gao, D., Tsou, P., Gan, W., Papa, A., Kim, B.M., et al. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 508 (2014), 541–545.
174. Liu, P., Gan, W., Chin, Y.R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L.C., Toker, A., et al. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex. Cancer Discov. 5 (2015), 1194–1209.
175. Lu, Y., Muller, M., Smith, D., Dutta, B., Komurov, K., Iadevaia, S., Ruths, D., Tseng, J.T., Yu, S., Yu, Q., et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 30 (2011), 4567–4577.
176. Lu, M., Wan, M., Leavens, K.F., Chu, Q., Monks, B.R., Fernandez, S., Ahima, R.S., Ueki, K., Kahn, C.R., Birnbaum, M.J., Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18 (2012), 388–395.
177. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., Pandolfi, P.P., Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005), 179–193.
178. Ma, C.X., Sanchez, C., Gao, F., Crowder, R., Naughton, M., Pluard, T., Creekmore, A., Guo, Z., Hoog, J., Lockhart, A.C., et al. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clin. Cancer Res. 22 (2016), 2650–2658.
179. Macintyre, A.N., Finlay, D., Preston, G., Sinclair, L.V., Waugh, C.M., Tamas, P., Feijoo, C., Okkenhaug, K., Cantrell, D.A., Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34 (2011), 224–236.
180. Maehama, T., Dixon, J.E., The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273 (1998), 13375–13378.
181. Mancini, M.L., Lien, E.C., Toker, A., Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget 7 (2016), 17301–17313.
182. Manning, B.D., Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167 (2004), 399–403.
183. Manning, B.D., Cantley, L.C., AKT/PKB signaling: navigating downstream. Cell 129 (2007), 1261–1274.
184. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., Cantley, L.C., Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10 (2002), 151–162.
185. Maroulakou, I.G., Oemler, W., Naber, S.P., Tsichlis, P.N., Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 67 (2007), 167–177.
186. Matsumoto, M., Pocai, A., Rossetti, L., Depinho, R.A., Accili, D., Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 6 (2007), 208–216.
187. Maurer, U., Charvet, C., Wagman, A.S., Dejardin, E., Green, D.R., Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21 (2006), 749–760.
188. Mayer, I.A., Arteaga, C.L., The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu. Rev. Med. 67 (2016), 11–28.
189. McManus, E.J., Collins, B.J., Ashby, P.R., Prescott, A.R., Murray-Tait, V., Armit, L.J., Arthur, J.S., Alessi, D.R., The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J. 23 (2004), 2071–2082.
190. McManus, E.J., Sakamoto, K., Armit, L.J., Ronaldson, L., Shpiro, N., Marquez, R., Alessi, D.R., Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 24 (2005), 1571–1583.
191. Mendoza, M.C., Er, E.E., Blenis, J., The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36 (2011), 320–328.
192. Menon, S., Dibble, C.C., Talbott, G., Hoxhaj, G., Valvezan, A.J., Takahashi, H., Cantley, L.C., Manning, B.D., Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156 (2014), 771–785.
193. Mercalli, A., Calavita, I., Dugnani, E., Citro, A., Cantarelli, E., Nano, R., Melzi, R., Maffi, P., Secchi, A., Sordi, V., Piemonti, L., Rapamycin unbalances the polarization of human macrophages to M1. Immunology 140 (2013), 179–190.
194. Mihaylova, M.M., Shaw, R.J., The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13 (2011), 1016–1023.
195. Moniz, L.S., Surinova, S., Ghazaly, E., Velasco, L.G., Haider, S., Rodríguez-Prados, J.C., Berenjeno, I.M., Chelala, C., Vanhaesebroeck, B., Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate. Sci. Rep., 7, 2017, 39985.
196. Mora, A., Komander, D., van Aalten, D.M., Alessi, D.R., PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15 (2004), 161–170.
197. Morel, C., Carlson, S.M., White, F.M., Davis, R.J., Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol. Cell. Biol. 29 (2009), 3845–3852.
198. Morrisett, J.D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C.M., Pownall, H.J., Opekun, A.R., Jaffe, J.S., Oppermann, S., Kahan, B.D., Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J. Lipid Res. 43 (2002), 1170–1180.
199. Mukai, Y., Rikitake, Y., Shiojima, I., Wolfrum, S., Satoh, M., Takeshita, K., Hiroi, Y., Salomone, S., Kim, H.H., Benjamin, L.E., et al. Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J. Clin. Invest. 116 (2006), 334–343.
200. Muranen, T., Selfors, L.M., Worster, D.T., Iwanicki, M.P., Song, L., Morales, F.C., Gao, S., Mills, G.B., Brugge, J.S., Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21 (2012), 227–239.
201. Navé, B.T., Ouwens, M., Withers, D.J., Alessi, D.R., Shepherd, P.R., Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344 (1999), 427–431.
202. Ng, Y., Ramm, G., Lopez, J.A., James, D.E., Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytes. Cell Metab. 7 (2008), 348–356.
203. Nixon, R.A., The role of autophagy in neurodegenerative disease. Nat. Med. 19 (2013), 983–997.
204. Ohanna, M., Sobering, A.K., Lapointe, T., Lorenzo, L., Praud, C., Petroulakis, E., Sonenberg, N., Kelly, P.A., Sotiropoulos, A., Pende, M., Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7 (2005), 286–294.
205. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S.E., Salpekar, A., Waterfield, M.D., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297 (2002), 1031–1034.
206. Okuzumi, T., Fiedler, D., Zhang, C., Gray, D.C., Aizenstein, B., Hoffman, R., Shokat, K.M., Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5 (2009), 484–493.
207. Omori, S.A., Cato, M.H., Anzelon-Mills, A., Puri, K.D., Shapiro-Shelef, M., Calame, K., Rickert, R.C., Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25 (2006), 545–557.
208. Ono, H., Shimano, H., Katagiri, H., Yahagi, N., Sakoda, H., Onishi, Y., Anai, M., Ogihara, T., Fujishiro, M., Viana, A.Y., et al. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52 (2003), 2905–2913.
209. Oshiro, N., Takahashi, R., Yoshino, K., Tanimura, K., Nakashima, A., Eguchi, S., Miyamoto, T., Hara, K., Takehana, K., Avruch, J., et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J. Biol. Chem. 282 (2007), 20329–20339.
210. Ouyang, W., Beckett, O., Ma, Q., Paik, J.H., DePinho, R.A., Li, M.O., Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat. Immunol. 11 (2010), 618–627.
211. Padmanabhan, S., Mukhopadhyay, A., Narasimhan, S.D., Tesz, G., Czech, M.P., Tissenbaum, H.A., A PP2A regulatory subunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation. Cell 136 (2009), 939–951.
212. Paradis, S., Ruvkun, G., Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes Dev. 12 (1998), 2488–2498.
213. Parikh, C., Janakiraman, V., Wu, W.I., Foo, C.K., Kljavin, N.M., Chaudhuri, S., Stawiski, E., Lee, B., Lin, J., Li, H., et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc. Natl. Acad. Sci. USA 109 (2012), 19368–19373.
214. Parker, P.J., Caudwell, F.B., Cohen, P., Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. Eur. J. Biochem. 130 (1983), 227–234.
215. Parsons, M.J., Jones, R.G., Tsao, M.S., Odermatt, B., Ohashi, P.S., Woodgett, J.R., Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. J. Immunol. 167 (2001), 42–48.
216. Phung, T.L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R.A., Shiojima, I., Nagy, J.A., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006), 159–170.
217. Poduri, A., Evrony, G.D., Cai, X., Elhosary, P.C., Beroukhim, R., Lehtinen, M.K., Hills, L.B., Heinzen, E.L., Hill, A., Hill, R.S., et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74 (2012), 41–48.
218. + T cell differentiation. J. Clin. Invest. 125 (2015), 2090–2108.
219. Polter, A., Beurel, E., Yang, S., Garner, R., Song, L., Miller, C.A., Sweatt, J.D., McMahon, L., Bartolucci, A.A., Li, X., Jope, R.S., Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 35 (2010), 1761–1774.
220. Porstmann, T., Santos, C.R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J.R., Chung, Y.L., Schulze, A., SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8 (2008), 224–236.
221. Potter, C.J., Pedraza, L.G., Xu, T., Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4 (2002), 658–665.
222. Puigserver, P., Rhee, J., Donovan, J., Walkey, C.J., Yoon, J.C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., Spiegelman, B.M., Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423 (2003), 550–555.
223. Ramm, G., Larance, M., Guilhaus, M., James, D.E., A role for 14-3-3 in insulin-stimulated GLUT4 translocation through its interaction with the RabGAP AS160. J. Biol. Chem. 281 (2006), 29174–29180.
224. Rhodes, N., Heerding, D.A., Duckett, D.R., Eberwein, D.J., Knick, V.B., Lansing, T.J., McConnell, R.T., Gilmer, T.M., Zhang, S.Y., Robell, K., et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68 (2008), 2366–2374.
225. Risso, G., Blaustein, M., Pozzi, B., Mammi, P., Srebrow, A., Akt/PKB: one kinase, many modifications. Biochem. J. 468 (2015), 203–214.
226. Roberts, M.S., Woods, A.J., Dale, T.C., Van Der Sluijs, P., Norman, J.C., Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. Mol. Cell. Biol. 24 (2004), 1505–1515.
227. Rodriguez-Viciana, P., Warne, P.H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M.J., Waterfield, M.D., Downward, J., Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370 (1994), 527–532.
228. Rodrik-Outmezguine, V.S., Chandarlapaty, S., Pagano, N.C., Poulikakos, P.I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., Rosen, N., mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 1 (2011), 248–259.
229. Romeo, Y., Zhang, X., Roux, P.P., Regulation and function of the RSK family of protein kinases. Biochem. J. 441 (2012), 553–569.
230. Rommel, C., Clarke, B.A., Zimmermann, S., Nuñez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G.D., Glass, D.J., Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286 (1999), 1738–1741.
231. Rommel, C., Bodine, S.C., Clarke, B.A., Rossman, R., Nunez, L., Stitt, T.N., Yancopoulos, G.D., Glass, D.J., Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3 (2001), 1009–1013.
232. Rosner, M., Siegel, N., Valli, A., Fuchs, C., Hengstschläger, M., mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids 38 (2010), 223–228.
233. Roux, P.P., Ballif, B.A., Anjum, R., Gygi, S.P., Blenis, J., Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA 101 (2004), 13489–13494.
234. Rudolph, M., Anzeneder, T., Schulz, A., Beckmann, G., Byrne, A.T., Jeffers, M., Pena, C., Politz, O., Köchert, K., Vonk, R., Reischl, J., AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer, 16, 2016, 622.
235. Rylatt, D.B., Aitken, A., Bilham, T., Condon, G.D., Embi, N., Cohen, P., Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur. J. Biochem. 107 (1980), 529–537.
236. Salhia, B., Van Cott, C., Tegeler, T., Polpitiya, A., Duquette, R.A., Gale, M., Hostteter, G., Petritis, K., Carpten, J., Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells. Hum. Mutat. 33 (2012), 1216–1227.
237. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S.M., Riggins, G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 2004, 554.
238. Sancak, Y., Thoreen, C.C., Peterson, T.R., Lindquist, R.A., Kang, S.A., Spooner, E., Carr, S.A., Sabatini, D.M., PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25 (2007), 903–915.
239. Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S.H., Goldberg, A.L., Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 (2004), 399–412.
240. Sanidas, I., Polytarchou, C., Hatziapostolou, M., Ezell, S.A., Kottakis, F., Hu, L., Guo, A., Xie, J., Comb, M.J., Iliopoulos, D., Tsichlis, P.N., Phosphoproteomics screen reveals akt isoform-specific signals linking RNA processing to lung cancer. Mol. Cell 53 (2014), 577–590.
241. Sano, H., Kane, S., Sano, E., Mîinea, C.P., Asara, J.M., Lane, W.S., Garner, C.W., Lienhard, G.E., Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J. Biol. Chem. 278 (2003), 14599–14602.
242. Sarbassov, D.D., Guertin, D.A., Ali, S.M., Sabatini, D.M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005), 1098–1101.
243. Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T., Pérez-Fidalgo, J.A., Morales-Barrera, R., Sanchis-García, J.M., Musib, L., Budha, N., et al. A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discov. 7 (2017), 102–113.
244. Saxton, R.A., Sabatini, D.M., mTOR Signaling in Growth, Metabolism, and Disease. Cell 168 (2017), 960–976.
245. Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., Nevins, J.R., Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14 (2000), 2501–2514.
246. Sekulić, A., Hudson, C.C., Homme, J.L., Yin, P., Otterness, D.M., Karnitz, L.M., Abraham, R.T., A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60 (2000), 3504–3513.
247. Shah, O.J., Hunter, T., Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol. Cell. Biol. 26 (2006), 6425–6434.
248. Shen, C.H., Yuan, P., Perez-Lorenzo, R., Zhang, Y., Lee, S.X., Ou, Y., Asara, J.M., Cantley, L.C., Zheng, B., Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol. Cell 52 (2013), 161–172.
249. Shi, L.Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D.R., Chi, H., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208 (2011), 1367–1376.
250. Siddiqui, N., Sonenberg, N., Signalling to eIF4E in cancer. Biochem. Soc. Trans. 43 (2015), 763–772.
251. So, L., Fruman, D.A., PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem. J. 442 (2012), 465–481.
252. Soliman, G.A., Acosta-Jaquez, H.A., Fingar, D.C., mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes. Lipids 45 (2010), 1089–1100.
253. Sommer, E.M., Dry, H., Cross, D., Guichard, S., Davies, B.R., Alessi, D.R., Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem. J. 452 (2013), 499–508.
254. Staal, S.P., Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. USA 84 (1987), 5034–5037.
255. Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15 (1997), 356–362.
256. Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge, D.C., Nik-Zainal, S., Martin, S., Varela, I., Bignell, G.R., et al., Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature 486 (2012), 400–404.
257. Stitt, T.N., Drujan, D., Clarke, B.A., Panaro, F., Timofeyva, Y., Kline, W.O., Gonzalez, M., Yancopoulos, G.D., Glass, D.J., The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14 (2004), 395–403.
258. Stokoe, D., Stephens, L.R., Copeland, T., Gaffney, P.R., Reese, C.B., Painter, G.F., Holmes, A.B., McCormick, F., Hawkins, P.T., Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277 (1997), 567–570.
259. Sundaresan, N.R., Pillai, V.B., Wolfgeher, D., Samant, S., Vasudevan, P., Parekh, V., Raghuraman, H., Cunningham, J.M., Gupta, M., Gupta, M.P., The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci. Signal., 4, 2011, ra46.
260. Suzuki, A., Yamaguchi, M.T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., Yoshida, R., Wakeham, A., Higuchi, T., Fukumoto, M., et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14 (2001), 523–534.
261. Tang, S.J., Reis, G., Kang, H., Gingras, A.C., Sonenberg, N., Schuman, E.M., A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl. Acad. Sci. USA 99 (2002), 467–472.
262. Tang, W., Zhang, Y., Xu, W., Harden, T.K., Sondek, J., Sun, L., Li, L., Wu, D., A PLCβ/PI3Kγ-GSK3 signaling pathway regulates cofilin phosphatase slingshot2 and neutrophil polarization and chemotaxis. Dev. Cell 21 (2011), 1038–1050.
263. Tang, H., Inoki, K., Lee, M., Wright, E., Khuong, A., Khuong, A., Sugiarto, S., Garner, M., Paik, J., DePinho, R.A., et al. mTORC1 promotes denervation-induced muscle atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin ligases. Sci. Signal., 7, 2014, ra18.
264. ter Haar, E., Coll, J.T., Austen, D.A., Hsiao, H.M., Swenson, L., Jain, J., Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8 (2001), 593–596.
265. Tschopp, O., Yang, Z.Z., Brodbeck, D., Dummler, B.A., Hemmings-Mieszczak, M., Watanabe, T., Michaelis, T., Frahm, J., Hemmings, B.A., Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132 (2005), 2943–2954.
266. Tzatsos, A., Kandror, K.V., Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol. Cell. Biol. 26 (2006), 63–76.
267. Um, S.H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P.R., Kozma, S.C., Auwerx, J., Thomas, G., Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004), 200–205.
268. van der Vos, K.E., Coffer, P.J., The extending network of FOXO transcriptional target genes. Antioxid. Redox Signal. 14 (2011), 579–592.
269. Vander Haar, E., Lee, S.I., Bandhakavi, S., Griffin, T.J., Kim, D.H., Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9 (2007), 316–323.
270. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., Bilanges, B., The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11 (2010), 329–341.
271. Vasudevan, K.M., Barbie, D.A., Davies, M.A., Rabinovsky, R., McNear, C.J., Kim, J.J., Hennessy, B.T., Tseng, H., Pochanard, P., Kim, S.Y., et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16 (2009), 21–32.
272. Vivanco, I., Chen, Z.C., Tanos, B., Oldrini, B., Hsieh, W.Y., Yannuzzi, N., Campos, C., Mellinghoff, I.K., A kinase-independent function of AKT promotes cancer cell survival. eLife, 3, 2014, e03751.
273. Wan, M., Leavens, K.F., Hunter, R.W., Koren, S., von Wilamowitz-Moellendorff, A., Lu, M., Satapati, S., Chu, Q., Sakamoto, K., Burgess, S.C., Birnbaum, M.J., A noncanonical, GSK3-independent pathway controls postprandial hepatic glycogen deposition. Cell Metab. 18 (2013), 99–105.
274. Wang, S., Huang, X., Sun, D., Xin, X., Pan, Q., Peng, S., Liang, Z., Luo, C., Yang, Y., Jiang, H., et al. Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. PLoS ONE, 7, 2012, e37427.
275. Wang, Y., Viscarra, J., Kim, S.J., Sul, H.S., Transcriptional regulation of hepatic lipogenesis. Nat. Rev. Mol. Cell Biol. 16 (2015), 678–689.
276. Wani, R., Qian, J., Yin, L., Bechtold, E., King, S.B., Poole, L.B., Paek, E., Tsang, A.W., Furdui, C.M., Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species. Proc. Natl. Acad. Sci. USA 108 (2011), 10550–10555.
277. Webb, A.E., Brunet, A., FOXO transcription factors: key regulators of cellular quality control. Trends Biochem. Sci. 39 (2014), 159–169.
278. Weichhart, T., Hengstschläger, M., Linke, M., Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 15 (2015), 599–614.
279. Welcker, M., Orian, A., Jin, J., Grim, J.E., Harper, J.W., Eisenman, R.N., Clurman, B.E., The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 101 (2004), 9085–9090.
280. Wisinski, K.B., Tevaarwerk, A.J., Burkard, M.E., Rampurwala, M., Eickhoff, J., Bell, M.C., Kolesar, J.M., Flynn, C., Liu, G., Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin. Cancer Res. 22 (2016), 2659–2667.
281. Xu, P.Z., Chen, M.L., Jeon, S.M., Peng, X.D., Hay, N., The effect Akt2 deletion on tumor development in Pten(+/-) mice. Oncogene 31 (2012), 518–526.
282. Yang, J., Cron, P., Good, V.M., Thompson, V., Hemmings, B.A., Barford, D., Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Biol. 9 (2002), 940–944.
283. Yang, W.L., Wang, J., Chan, C.H., Lee, S.W., Campos, A.D., Lamothe, B., Hur, L., Grabiner, B.C., Lin, X., Darnay, B.G., Lin, H.K., The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325 (2009), 1134–1138.
284. Yi, K.H., Lauring, J., Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. Oncotarget 7 (2016), 4241–4251.
285. Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, S., Kikuchi, A., Kaibuchi, K., GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120 (2005), 137–149.
286. You, J.S., Anderson, G.B., Dooley, M.S., Hornberger, T.A., The role of mTOR signaling in the regulation of protein synthesis and muscle mass during immobilization in mice. Dis. Model. Mech. 8 (2015), 1059–1069.
287. Yu, Y., Yoon, S.O., Poulogiannis, G., Yang, Q., Ma, X.M., Villén, J., Kubica, N., Hoffman, G.R., Cantley, L.C., Gygi, S.P., Blenis, J., Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332 (2011), 1322–1326.
288. Yu, Y., Savage, R.E., Eathiraj, S., Meade, J., Wick, M.J., Hall, T., Abbadessa, G., Schwartz, B., Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS ONE, 10, 2015, e0140479.
289. Zhu, L., Yang, T., Li, L., Sun, L., Hou, Y., Hu, X., Zhang, L., Tian, H., Zhao, Q., Peng, J., et al. TSC1 controls macrophage polarization to prevent inflammatory disease. Nat. Commun., 5, 2014, 4696.
290. Zhuang, G., Yu, K., Jiang, Z., Chung, A., Yao, J., Ha, C., Toy, K., Soriano, R., Haley, B., Blackwood, E., et al. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci. Signal., 6, 2013, ra25.
291. Zimmermann, S., Moelling, K., Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286 (1999), 1741–1744.